Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: Preliminary results

This publication has 28 references indexed in Scilit:

• Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2
  European Journal of Cancer and Clinical Oncology, 1991
• Neuroendocrine strategy with the pineal hormone melatonin (MLT) to enhance the antitumor activity interleukin-2 (IL-2)
  European Journal of Cancer and Clinical Oncology, 1990
• Continuous infusion recombinant interleukin-2 (rIL-2) in adoptive cellular therapy of renal carcinoma and other malignancies
  Cancer Treatment Reviews, 1989
• Endocrine and immune effects of melatonin therapy in metastatic cancer patients
  European Journal of Cancer and Clinical Oncology, 1989
• A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone
  New England Journal of Medicine, 1987
• Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer
  New England Journal of Medicine, 1987
• Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer
  New England Journal of Medicine, 1985
• Circadian variation of lymphocyte subpopulations: a study with monoclonal antibodies.
  BMJ, 1983
• Enkephalins as immunomodulators
  International Journal of Immunopharmacology, 1983
• T cell growth factor receptors. Quantitation, specificity, and biological relevance
  The Journal of Experimental Medicine, 1981